Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Reisa A. Sperling(Harvard University), Karen C. Holdridge(Eli Lilly (United States)), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Paul Aisen(University of California, San Diego), Chung‐Kai Sun(National Yang Ming Chiao Tung University), Rema Raman(University of Southern California), Eric Siemers(Eli Lilly (United States)), Keith A. Johnson(Brigham and Women's Hospital), R. Yaari(Eli Lilly (United States))
Cited by 330
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k